LB Pharmaceuticals Inc (LBRX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Ami Fadia
Needham & Company, LLC, Research Division

Good morning, everyone. I’m Ami Fadia, biotech analyst here at Needham. Welcome to the next session with LB Pharmaceuticals. It’s my pleasure to be hosting Heather Turner, CEO of the company.

Heather, thank you so much for participating in our conference and taking the time for this session. I will turn it over to you for the presentation, and we’ll have some time at the end for Q&A. And maybe this is a good time to remind our listeners that they can send me any questions that they’d like me to ask through the dashboard.

With that, over to you, Heather.

Heather Turner
CEO & Director

Thank you, Ami, for including us in this conference today. We’re really happy to be here in the Zoomaverse with you all. I will be making forward-looking statements today.

The vision for LB Pharma is to build a fully integrated company focused on CNS-related diseases. This company would be ready, willing and capable to successfully launch a therapeutic when we find ourselves with an approved asset. We have a late-stage asset LB-102 in schizophrenia, bipolar depression and adjunctive MDD.

We presented Phase II data from a schizophrenia trial last year. And from that, we think we have an opportunity for a very differentiated profile in what is a very large branded antipsychotic market. Coming out of that Phase II trial, we engaged with the FDA. And with that engagement, we believe there’s a streamlined path to approval in schizophrenia with just a single Phase III clinical trial.

We